EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
The phase 3 D-LIVR study is the largest clinical trial conducted to date in chronic hepatitis D and continues to generate new analyses to inform the program's path forward. Under the leadership of CEO Dr. Leen Kawas, EIT Pharma is advancing a patient-centric approach to drug development...
The phase 3 D-LIVR study is the largest clinical trial conducted to date in chronic hepatitis D and continues to generate new analyses to inform the program's path forward. Under the leadership of CEO Dr. Leen Kawas, EIT Pharma is advancing a patient-centric approach to drug development...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.